Literature DB >> 28400622

Viral hepatitis: The bumpy road to animal models for HBV infection.

Ulrike Protzer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28400622     DOI： 10.1038/nrgastro.2017.44

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Construction of recombinant adenoviruses that produce infectious hepatitis B virus.

Authors:  Martin Sprinzl; Jérôme Dumortier; Ulrike Protzer
Journal:  Methods Mol Med       Date:  2004

2.  Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.

Authors:  Florian A Lempp; Ellen Wiedtke; Bingqian Qu; Pierre Roques; Isabelle Chemin; Florian W R Vondran; Roger Le Grand; Dirk Grimm; Stephan Urban
Journal:  Hepatology       Date:  2017-07-18       Impact factor: 17.425

3.  Chimeric mouse model of hepatitis B virus infection.

Authors:  Maura Dandri; Jörg Petersen
Journal:  J Hepatol       Date:  2011-07-27       Impact factor: 25.083

4.  HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA.

Authors:  Zhipeng Yan; Jing Zeng; Youjun Yu; Kunlun Xiang; Hui Hu; Xue Zhou; Lili Gu; Li Wang; Jie Zhao; John A T Young; Lu Gao
Journal:  J Hepatol       Date:  2017-02-14       Impact factor: 25.083

Review 5.  Experimental in vitro and in vivo models for the study of human hepatitis B virus infection.

Authors:  Lena Allweiss; Maura Dandri
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

6.  Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.

Authors:  Huan Yan; Bo Peng; Yang Liu; Guangwei Xu; Wenhui He; Bijie Ren; Zhiyi Jing; Jianhua Sui; Wenhui Li
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

7.  Immune effectors required for hepatitis B virus clearance.

Authors:  Priscilla L Yang; Alana Althage; Josan Chung; Holly Maier; Stefan Wieland; Masanori Isogawa; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

8.  High-level hepatitis B virus replication in transgenic mice.

Authors:  L G Guidotti; B Matzke; H Schaller; F V Chisari
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules.

Authors:  Sarah Dion; Maryline Bourgine; Ophélie Godon; Florence Levillayer; Marie-Louise Michel
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

10.  Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice.

Authors:  Li-Rung Huang; Yvonne A Gäbel; Steffi Graf; Silke Arzberger; Christian Kurts; Mathias Heikenwalder; Percy A Knolle; Ulrike Protzer
Journal:  Gastroenterology       Date:  2012-03-14       Impact factor: 22.682
  10 in total
  6 in total

1.  In Vivo Bioluminescence Imaging of HBV Replicating Hepatocytes Allows for the Monitoring of Anti-Viral Immunity.

Authors:  Katrin Manske; Annika Schneider; Chunkyu Ko; Percy A Knolle; Katja Steiger; Ulrike Protzer; Dirk Wohlleber
Journal:  Viruses       Date:  2021-11-13       Impact factor: 5.048

2.  Rapid and Robust Continuous Purification of High-Titer Hepatitis B Virus for In Vitro and In Vivo Applications.

Authors:  Jochen M Wettengel; Bianca Linden; Knud Esser; Michael Laue; Benjamin J Burwitz; Ulrike Protzer
Journal:  Viruses       Date:  2021-07-30       Impact factor: 5.048

3.  Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma.

Authors:  Tanvir Hossain; Shahla Romal; Elisa De Crignis; Fabrizia Carofiglio; Panagiotis Moulos; Mir Mubashir Khalid; Shringar Rao; Ameneh Bazrafshan; Monique Ma Verstegen; Farzin Pourfarzad; Christina Koutsothanassis; Helmuth Gehart; Tsung Wai Kan; Robert-Jan Palstra; Charles Boucher; Jan Nm IJzermans; Meritxell Huch; Sylvia F Boj; Robert Vries; Hans Clevers; Luc Jw van der Laan; Pantelis Hatzis; Tokameh Mahmoudi
Journal:  Elife       Date:  2021-07-30       Impact factor: 8.140

4.  Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models.

Authors:  Michelle P Clark; Thao Huynh; Peter Revill; Marc Pellegrini; Gregor Ebert; Shringar Rao; Liana Mackiewicz; Hugh Mason; Shahla Romal; Michael D Stutz; Sang H Ahn; Linda Earnest; Vitina Sozzi; Margaret Littlejohn; Bang M Tran; Norbert Wiedemann; Elizabeth Vincan; Joseph Torresi; Hans J Netter; Tokameh Mahmoudi
Journal:  Cell Death Dis       Date:  2021-06-23       Impact factor: 8.469

Review 5.  Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.

Authors:  Florian A Lempp; Stephan Urban
Journal:  Viruses       Date:  2017-07-04       Impact factor: 5.048

6.  Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies.

Authors:  Wai-Kay Seto
Journal:  World J Gastroenterol       Date:  2019-01-21       Impact factor: 5.742
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.